Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24 Week Study Followed by Long-Term Treatment for Evaluation of Efficacy and Safety of Baricitinib in Patients with Active Psoriatic Arthritis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24 Week Study Followed by Long-Term Treatment for Evaluation of Efficacy and Safety of Baricitinib in Patients with Active Psoriatic Arthritis

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 30 Apr 2019 Status changed from planning to withdrawn prior to enrolment, according to an Incyte Corporation media release, as Eli Lilly no longer plans to initiate Phase 3 development of baricitinib for psoriatic arthritis.
    • 04 Sep 2017 According to an Eli Lilly media release, this trial is scheduled to begin in 2018.
    • 01 Aug 2017 According to an Incyte Corporation media release, Lilly no longer plans to initiate a Phase III program to evaluate the safety and efficacy of baricitinib in patients with PsA during 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top